Press Releases
[May 2012] New Board Members join PolyTherics
ENHANCED BREADTH OF EXPERIENCE ON POLYTHERICS’ BOARD SUPPORTS NEXT PHASE OF DEVELOPMENT
London, UK, 15 May 2012 – PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, is pleased to announce that Dr Anker Lundemose and Nigel Pitchford have joined its Board.
[Apr 2012] PolyTherics Announces a Research Collaboration with Spirogen to Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
COMPANIES WILL COMBINE SITE-SPECIFIC CONJUGATION WITH NOVEL POTENT CYTOTOXICS
London, UK, 2 April 2012 – PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, announces that it has formed a research collaboration with Spirogen Limited ("Spirogen"), a leading oncology-focused company developing DNA sequence-targeted agents, to develop antibody-drug conjugates (ADCs) that combine PolyTherics’ proprietary site-specific conjugation chemistry with Spirogen’s highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.
[Jan 2012] PolyTherics acquires Warwick Effect Polymers and expands technology portfolio to enable the development of better biopharmaceuticals
ENHANCED OFFERING INCLUDES LOW VISCOSITY POLYMERS FOR CREATION OF LONGER-ACTING DRUGS AND A NOVEL DRUG TARGETING TECHNOLOGY
London, UK, 20 January 2012 – PolyTherics Limited (“PolyTherics”), a provider of solutions to biopharmaceutical companies for the improvement of protein and peptide based drugs, is pleased to announce the acquisition of Warwick Effect Polymers (“WEP”), a provider of specialty biopolymers for the modification of biological products.
